10-Q: Lipella Pharmaceuticals Delisted from Nasdaq, Faces Going Concern Doubts

Lipella Pharmaceuticals Inc. reported increased net losses and was delisted from Nasdaq, raising substantial doubt about its ability to continue as a going concern, despite clinical progress.

Summary

• Lipella Pharmaceuticals Inc. reported a net loss of $2,634,009 for the six months ended June 30, 2025, an increase from $2,129,955 for the same period in 2024.
• Grant revenues decreased to $216,117 for the six months ended June 30, 2025, from $282,311 in the prior year, as grant funds were fully depleted.
• Research and development expenses increased by $280,898 to $1,785,056 for the six months ended June 30, 2025, primarily due to increased outside services for the LP-310 clinical trial and salaries/benefits.
• General and administrative expenses rose by $167,469 to $1,115,457 for the six months ended June 30, 2025, mainly due to higher professional and outside services costs.
• The company's common stock was delisted from the Nasdaq Capital Market on June 20, 2025, due to non-compliance with shareholder approval and voting rights requirements, and now trades on the OTCID Market under the symbol LIPO.
• Management expressed substantial doubt about the company's ability to continue as a going concern, citing historical losses and the need for significant additional capital.
• Cash and cash equivalents increased to $2,781,828 as of June 30, 2025, from $2,184,863 at December 31, 2024, primarily due to $3,456,228 in net cash provided by financing activities.
• The Phase 2a clinical trial for LP-310 completed dosing for the first cohort with no product-related serious adverse events and minimal systemic exposure, with top-line data from the first two dose cohorts presented on May 15, 2025.
• LP-410 received orphan drug designation from the FDA on November 11, 2023, and Investigational New Drug (IND) approval on March 5, 2024, for oral graft-versus-host disease (GVHD).

Sentiment

Score: 3

Explanation: The sentiment is negative due to the Nasdaq delisting, the 'going concern' warning, and increasing net losses. While there is positive clinical progress and a recent capital raise, these are overshadowed by severe financial instability, reduced market liquidity, and the high risk of further dilution.

Positives

• Successfully completed dosing for the first cohort in the Phase 2a clinical trial of LP-310 with no product-related serious adverse events reported.
• Pharmacokinetic data for LP-310 demonstrated undetectable or minimal whole blood tacrolimus levels, indicating potential for localized therapeutic effects with minimal systemic exposure.
• Patients tolerated LP-310 without significant adverse reactions, suggesting a favorable safety profile.
• LP-410 received Orphan Drug Designation from the FDA and IND approval, marking significant regulatory progress for a rare disease with no currently approved local treatment.
• Cash and cash equivalents increased to $2,781,828 as of June 30, 2025, from $2,184,863 at December 31, 2024, bolstered by recent financing activities.
• The company holds two issued U.S. patents for LP-10 and LP-310 formulations, providing intellectual property protection until July 11, 2035, with additional patents in Australia, Canada, and Europe.

Negatives

• Net loss significantly increased to $2,634,009 for the six months ended June 30, 2025, compared to $2,129,955 for the same period in 2024.
• Grant revenues decreased due to the full depletion of awarded funds from the 2022 NIH Grant.
• The company's common stock was delisted from the Nasdaq Capital Market on June 20, 2025, and now trades on the less liquid OTCID Market.
• Management explicitly stated 'substantial doubt about the Company's ability to continue as a going concern' due to historical losses and the need for significant additional capital.
• The common stock is deemed a 'penny stock,' which limits liquidity and makes it more difficult for broker-dealers to recommend.
• Issuance of Common Stock upon conversion of Series B and Series C Preferred Stock, and exercise of Series B Warrants, will cause immediate dilution to existing shareholders.
• The rights of holders of Series B Preferred Stock rank senior to Common Stock holders regarding dividends and payments upon liquidation.

Risks

• The company may never be able to satisfy the listing requirements for its Common Stock to be relisted on a national securities exchange, which could cause trading to suffer, reduce liquidity, and increase price volatility.
• The designation of the Common Stock as a 'penny stock' limits its liquidity, as prices may not be readily available, and many brokers and investors may choose not to participate in such transactions.
• The issuance of Common Stock upon conversion of Series B and Series C Preferred Stock, and the exercise of Series B Warrants, will cause immediate dilution to existing shareholders and could lead to a decline in stock price.
• The rights of holders of Series B Preferred Stock rank senior to Common Stock holders regarding dividends and payments upon liquidation, potentially disadvantaging common shareholders.
• The company has incurred historical losses and anticipates continued operating losses, raising substantial doubt about its ability to continue as a going concern without significant additional capital.
• Future funding requirements are uncertain and could increase significantly, and adequate funding may not be available on acceptable terms, potentially forcing delays, scaling back, or discontinuation of development programs, or cessation of operations.

Future Outlook

The company anticipates operating losses to continue for the foreseeable future and will require significant additional capital to continue its research and development programs, including progressing clinical product candidates to commercialization. Existing cash and cash equivalents are expected to fund operations and capital expenses through the end of 2025. The LP-310 clinical trial is expected to be completed in the third quarter of 2025. The company does not intend to utilize its At The Market Offering due to the Nasdaq delisting.

Management Comments

• "We believe that this strategy combines many of the cost efficiencies and risk abatements derived from using existing generic drugs with potential patent protections for our proprietary formulations; this strategy allows us to expedite, protect, and monetize our product candidates."
• "Additionally, we maintain a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists."
• "We expect that our R&D expenses will increase substantially in connection with our clinical development activities for our LP-10 and LP-310 programs, and other product candidates."
• "Our ability to transition attaining profitable operations is dependent upon achieving a level of revenues adequate to support our cost structure."
• "To date, upon review of relevant FDA public data resources on approved drugs and biologics, we are not aware of any other liposomal products developed to treat such disease [OLP]."

Industry Context

Lipella Pharmaceuticals operates in the clinical-stage biotechnology sector, focusing on drug reformulation to leverage existing generic active agents for new applications. This strategy aims to reduce development costs and risks while potentially securing new patent protections. The company targets diseases with significant unmet medical needs, such as hemorrhagic cystitis, oral lichen planus, and oral graft-versus-host disease, where approved therapies are lacking. This niche focus can potentially expedite regulatory approval processes. The development of liposomal tacrolimus for oral lichen planus is highlighted as a novel approach within the industry, with no other known similar products.

Comparison to Industry Standards

• The company's strategy of reformulating existing generic drugs for new applications is a common de-risking approach in the biotechnology industry, aiming to reduce development timelines and costs compared to novel drug discovery.
• The successful completion of dosing for the first cohort of the LP-310 Phase 2a trial, with no serious adverse events and minimal systemic exposure, indicates a positive safety profile for a clinical-stage asset, aligning with industry goals for localized drug delivery.
• Receiving Orphan Drug Designation and IND approval for LP-410 for oral GVHD demonstrates progress in addressing rare diseases, a segment often supported by regulatory incentives, comparable to other biotechs pursuing orphan indications.
• The Nasdaq delisting is a significant negative outlier compared to industry standards for publicly traded biotechnology companies, as it severely impacts market visibility, liquidity, and investor confidence, unlike peers maintaining national exchange listings.
• The company's accumulated deficit and 'going concern' warning are indicative of the high capital intensity and inherent risks in early-stage biotech, though the severity of the going concern warning suggests a more precarious financial position than many clinical-stage peers.

Corporate Governance

Related Party Transactions

• The company has a letter of credit with a bank for $50,000, collateralized by substantially all of the company's assets and personally guaranteed by Dr. Jonathan Kaufman, the Chief Executive Officer. The outstanding balance was $0 at June 30, 2025 and December 31, 2024.
• Pursuant to an irrevocable proxy and power of attorney, Spartan Capital Securities, LLC agreed to grant Dr. Jonathan Kaufman all voting power over and power of attorney with respect to all shares of Series C Preferred Stock and all shares of Common Stock issuable upon conversion of such shares or exercise of common stock purchase warrants issued or issuable to Spartan or its designee in connection with the Offering.

Stakeholder Impact

• Shareholders face significant negative impact due to the Nasdaq delisting, resulting in reduced liquidity and market visibility, and the common stock being designated as a 'penny stock.'
• Existing common shareholders will experience immediate and potential future dilution from the conversion of Series B and Series C Preferred Stock and the exercise of Series B Warrants.
• Holders of Series B Preferred Stock have senior rights regarding dividends and liquidation payments compared to common shareholders.
• Employees may face uncertainty due to the 'going concern' warning, although ongoing R&D activities suggest continued operations in the short term.
• Creditors may view the 'going concern' warning as an increased risk to the company's ability to meet its financial obligations.
• Patients and the medical community could potentially benefit from the successful development of the company's drug candidates for unmet medical needs, but this is contingent on the company's ability to secure future funding and achieve regulatory approvals.

Next Steps

• Completion of the Phase 2a clinical trial for LP-310, expected in the third quarter of 2025.
• Continued research and development activities for LP-10, LP-310, LP-410, and LP-50.
• Securing significant additional capital to fund ongoing operations and advance product candidates to commercialization.
• Potential efforts to relist common stock on a national securities exchange, though this is not assured.

Key Dates

Recommendation

The company faces critical challenges, including a significant increase in net losses, an explicit 'going concern' warning, and the highly detrimental delisting from Nasdaq to the less liquid OTC market. These factors severely undermine investor confidence and operational stability. While there is some positive clinical progress, the fundamental financial and governance risks are overwhelming, suggesting a high probability of further share price decline and potential operational distress. The recent capital raise is insufficient to offset the ongoing cash burn and the stated need for 'significant additional capital,' which will likely come at highly dilutive terms. This combination of factors makes the stock a strong sell for investors.

Keywords

Biotechnology, Clinical-stage, SEC Filing, 10-Q, Nasdaq Delisting, Going Concern, Drug Development, Hemorrhagic Cystitis, Oral Lichen Planus, Oral GVHD, LP-10, LP-310, LP-410, Orphan Drug, Clinical Trials, Financial Performance, Dilution, OTC Markets